Posted by Michael Wonder on 17 Jan 2026
Novartis ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease
16 January 2026 - Novartis today announced that the US FDA has granted breakthrough therapy designation to ianalumab for Sjögren’s disease, the second most prevalent rheumatic autoimmune disease.
Ianalumab is a fully human monoclonal antibody with a novel dual mechanism of action that depletes B-cells and inhibits their activation and survival via BAFF-R blockade.
